ClinicalTrials.gg
RecruitingNCT05456893ImmUniverseUpdated May 6, 2025

A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies

An observational study in Ulcerative Colitis and Inflammatory Bowel Diseases, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
95
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 239 studies in Colitis, Ulcerative with a site in France — 45 open to participants now, 78 under way, 27 of them phase 3. Colitis, Ulcerative · France.

Planned enrollment
45th of 55
95 · median 360
Started
2022
with 14 others
Observational
55 of 239
13 open now
Primary completion
2027-09
later than 41 of 77 live
Registered
167th of 239
by date

Among the 239 studies in Colitis, Ulcerative with a site in France, this one is the 45th largest by planned enrollment of the 55 observational ones that give a count, is one of 15 that started in 2022, is one of 55 observational ones, reaches primary completion later than 41 of the 77 other live ones, and was the 167th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

45 of the 239 studies in Colitis, Ulcerative with a site in France are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 239 studies in Colitis, Ulcerative with a site in France, or all of them as a file.
02

Study summary

UC is a chronic, idiopathic form of intestinal inflammatory disease (IBD) that affects the colon, most commonly afflicting adults aged 30-40 years and resulting in disability and lower quality of life (1). It is characterized by relapsing and remitting mucosal inflammation, starting in the rectum and extending to proximal segments of the colon. Although biologic therapies have provided clinical benefits to patients, these goals are still poorly met, due to the limited knowledge of the underlying mechanisms of immunopathology and the lack of predictive biomarkers that would allow proper patient stratification.

The hypothesis of this study is that by identifying new biomarkers in blood, stool and tissue that (i) predict response (or non-response) to therapy prior to the start of treatment and (ii) predict response to therapy in the early phase of treatment will allow to find the right treatment for the right patient (personalized medicine).

03

Conditions studied

  • Ulcerative Colitis
  • Inflammatory Bowel Diseases

Keywords

  • Ulcerative Colitis
  • Immune-Mediated Inflammatory Diseases
  • Biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with moderate to severe active UC with an indication to start a biologic treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients ≥ 18 years of age (at the time of signing the ICF)
  • Established diagnosis of ulcerative colitis with a minimum disease duration of 3 months
  • Moderate to severe active UC defined by Mayo Score ≥ 6
  • Moderate to severe active UC defined by endoscopy score of ≥2
  • Indication to start any biological or small molecule agent (anti-TNF, anti- IL12/23, anti-integrin and JAK-inhibitors)
  • In case of treatment with : stable dose for at least 3 weeks prior to baseline, dosage ≤ 20 mg prednisone
  • Indication for an endoscopy for the assessment of disease activity as for standards of care and current guidelines
  • Able to comply with the study procedures
  • Person affiliated to or beneficiary of a social security plan
  • Person informed about study organization and able to sign form

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, microscopic colitis, ischaemic colitis, infectious colitis, radiation colitis
  • Absolute to endoscopy procedures or complication during previous endoscopy
  • Bleeding disorders
  • Indication for surgery for UC
  • Rectal topical therapy (enemas or suppositories) ≤ 2 weeks prior to baseline
  • Treatment with > 20 mg prednisone within 3 weeks prior to baseline
  • Anaemia ( \< 10 g/dl) at baseline
  • Any circumstances which could contradict a study participation and lead the Investigator to assess the patient as unsuitable for study participation for any other reason
  • Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the Public Health Code:

    • Pregnant, parturient or breastfeeding woman
    • Minor person (non-emancipated)
    • Adult person under legal protection (any form of public guardianship)
    • Adult person incapable of giving consent and not under legal protection
  • Person deprived of liberty for judicial or administrative decision, person under psychiatric care as referred in articles L. 3212-1 and L. 3213-1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
95 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • UC patients

    All patients with an established ulcerative colitis

    Procedure: Procedure: endoscopic biopsy · Procedure: Blood sampling · Procedure: stool sampling

Interventions

  • ProcedureProcedure: endoscopic biopsy

    Per-endoscopic biopsies

  • ProcedureBlood sampling

    Blood sampling

  • Procedurestool sampling

    stool sampling

06

What researchers measure

Primary outcomes

  1. The percentage of subjects who achieve clinical response at week 14.

    Clinical response will be defined as overall Mayo score of 2 or smaller with Mayo endoscopy score (Mayo ES) of 0 or 1 (without friability), and bleeding subscore of 0. The Clinical Response will be categorized in four subcategories: * Super responder: meets criteria of clinical response * Responder: Mayo Score: reduction of 50%/ improvement of ≥ 3 from baseline, but does not meet criteria of remission; endoscopic Mayo: does not meet criteria of clinical response, but shows reduction of Mayo ES * Partial responder: Mayo Score: reduction of up to 30%, endoscopic Mayo: no formal improvement by Mayo ES but in overall assessment by the physician slight improvement. * Non-responder: reduction of less than 30% and in endoscopy no improvement in the overall assessment

    Time frame: The percentage of subjects who achieve clinical response at week 14

  2. The percentage of subjects who achieve deep clinical remission at week 14.

    Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) ≤1 and rectal bleeding (RB) = 0.

    Time frame: The percentage of subjects who achieve deep clinical remission at week 14

  3. The percentage of subjects who achieve deep clinical remission at week 26.

    Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) ≤1 and rectal bleeding (RB) = 0.

    Time frame: The percentage of subjects who achieve deep clinical remission at week 26.

  4. The percentage of subjects who achieve deep clinical remission at week 52.

    Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) ≤1 and rectal bleeding (RB) = 0.

    Time frame: The percentage of subjects who achieve deep clinical remission at week 52.

  5. The percentage of subjects who achieve mucosal healing at week 14.

    Mucosal healing will be defined as Mayo endoscopic score = 0; Nancy histology index: ulceration: 0, neutrophils: 0, chronic infiltrate: 0 or 1.

    Time frame: The percentage of subjects who achieve mucosal healing at week 14.

  6. The percentage of subjects who achieve mucosal healing at week 52.

    Mucosal healing will be defined as Mayo endoscopic score = 0; Nancy histology index: ulceration: 0, neutrophils: 0, chronic infiltrate: 0 or 1.

    Time frame: The percentage of subjects who achieve mucosal healing at week 52.

  7. The percentage of subjects who achieve symptomatic remission at week 14.

    Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).

    Time frame: The percentage of subjects who achieve symptomatic remission at week 14.

  8. The percentage of subjects who achieve symptomatic remission at week 26.

    Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).

    Time frame: The percentage of subjects who achieve symptomatic remission at week 26.

  9. The percentage of subjects who achieve symptomatic remission at week 52.

    Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).

    Time frame: The percentage of subjects who achieve symptomatic remission at week 52.

Secondary outcomes

  1. The percentage of subjects without any disease progression (e.g. flares) at week 14.

    The percentage of subjects without any disease progression (e.g. flares) at week 14.

    Time frame: The percentage of subjects without any disease progression (e.g. flares) at week 14.

  2. The percentage of subjects without any disease progression (e.g. flares) at week 26.

    The percentage of subjects without any disease progression (e.g. flares) at week 26.

    Time frame: The percentage of subjects without any disease progression (e.g. flares) at week 26.

  3. The percentage of subjects without any disease progression (e.g. flares) at week 52.

    The percentage of subjects without any disease progression (e.g. flares) at week 52.

    Time frame: The percentage of subjects without any disease progression (e.g. flares) at week 52.

  4. The percentage of subjects who show an improvement on patient reported outcomes at week 14.

    Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).

    Time frame: The percentage of subjects who show an improvement on patient reported outcomes at week 14.

  5. The percentage of subjects who show an improvement on patient reported outcomes at week 26.

    Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).

    Time frame: The percentage of subjects who show an improvement on patient reported outcomes at week 26.

  6. The percentage of subjects who show an improvement on patient reported outcomes at week 52.

    Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).

    Time frame: The percentage of subjects who show an improvement on patient reported outcomes at week 52.

  7. The percentage of subjects without the following complications until week 52 :

    The percentage of subjects without the following complications until week 52: * hospitalizations due to UC * treatment intensification including introduction of toxic long-term therapies (i.e. systemic glucocorticoids) * new stenosis * new fistula * new development of primary sclerosing cholangitis (PSC) * infections * intestinal surgery

    Time frame: week 52

  8. The percentage of subjects without long-term complications until week 104.

    The percentage of subjects without long-term complications until week 104.

    Time frame: The percentage of subjects without long-term complications until week 104.

07

Study locations

1 of 1 sites recruiting
  • Central Hospital
    Nancy, Lorraine 54500, France
    Recruiting
    • Laurent MD PEYRIN-BIROULET, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Sep 2027, 61 months after the start.

Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 61 months is above that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 13, 2022
StartActual
Jul 28, 2022
Primary completionEst.
Sep 9, 2027
CompletionEst.
Sep 9, 2027
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05456893
Responsible party
Dr Laurent PEYRIN-BIROULET (Principal Investigator (France), Central Hospital, Nancy, France) — Principal investigator
First posted
Jul 13, 2022
Start date
Jul 28, 2022
Primary completion
Sep 9, 2027 (estimated)
Completion
Sep 9, 2027 (estimated)
Last update
May 6, 2025

Study contacts

Laurent MD Peyrin-Biroulet, PhD
Contact
peyrinbiroulet@gmail.com
0383153661
Stefan MD SCHREIBER, PhD
study director · Christian Albrechts Universität

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion